Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Агонист дофаминовых рецепторов пирибедил в лечении болезни Паркинсона
Агонист дофаминовых рецепторов пирибедил в лечении болезни Паркинсона
С.Н.Иллариошкин, Е.А.Карпова, И.А.Иванова-Смоленская, Л.А.Черникова. Агонист дофаминовых рецепторов пирибедил в лечении болезни Паркинсона. Consilium Medicum. Неврология (Прил.). 2013; 1: 25-29.
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Левин О.С., Федорова Н.В. Болезнь Паркинсона. М.: МЕДпресс-информ, 2012.
2. Schapira AHV. The management of Parkinson’s disease – what is new? Eur J Neurol 2011; 18 (Suppl. 1): 1–2.
3. Иллариошкин С.Н. Терапия паркинсонизма: возможности и перспективы. Cons. Med. Неврология (Прил.). 2009; 1: 35–40.
4. Poewe W, Antonini A, Zijlmans JC et al. Levodopa in the treatment of Parkinson's disease: an old drug still going strong Clin Interv Aging 2010; 7: 229–38.
5. Quinn N. Drug treatment of Parkinson’s disease. BMJ 1995; 310 (Suppl. 9): 575−9.
6. Rascol O, Slaoui T, Regragui W et al. Dopamine agonists. W.C.Koller, E.Melamed (eds). Handbook of Clinical Neurology; v. 84: Parkinson’s disease and related disorders. Part II. Elsevier 2007; p. 73–92.
7. Sibley DR, Monsma FJ. Trends Pharmacol Sci 1992; 13: 63–9.
8. Rodbell M. Signal transduction: evolution of an idea. N.Ringertz (ed). Nobel Lectures, Physiology or Medicine 1991–1995. Singapore: World Scientific, 1997; p. 220–36.
9. Schapira AHV, Olanow CW. Neuroprotection in Parkinson’s disease. Mysteries, Myths, and Misconceptions. JAMA 2003; 291: 358–64.
10. Nishibayashi S, Asanuma M, Kohno M et al. Scavenging effects of dopamine agonists on nitric oxide radicals. J Neurochem 1996; 67: 2208–11.
11. Stocchi F. Neuroprotection in Parkinson’s disease: clinical trials. W.C.Koller, E.Melamed (eds). Handbook of Clinical Neurology, Vol.84: Parkinson’s disease and related disorders. Part II. Elsevier 2007; 17–29.
12. Голубев В.Л., Садеков Р.А., Пилипович А.А. Проноран в лечении болезни Паркинсона. Лечение нервных болезней. 2002; 3: 13–7.
13. Kwiecinski H, Fedorova N, Takats A et al. A multicenter trial of Piribedil as early adjunct treatment for Parkinson’s disease: Piribedil International Study Group (PISG). Neurology 2002; 58: A163.
14. Truelle JL, Chanelet J, Bastard J et al. Piribedil, dopaminergic agonist: prolonged clinical and electrophysiological study in 60 parkinsonian patients. Presse Med 1977; 6: 2987–90.
15. Ziegler M, Rondot P. Activity of piribedil in Parkinson’s disease: a multicenter study. Press Med 1999; 28: 1414–8.
16. Пилипович А.А., Голубев В.Л. Влияние пронорана на когнитивные и аффективные нарушения при болезни Паркинсона. Журн. неврол. и психиатр. им. С.С.Корсакова. 2005; 4: 41–7.
17. Millan MJ, Cussac D, Milligan G et al. Antiparkinsonian agent Piribedil displays antagonism properties at native, rat, and cloned, human a2-adrenoreceptors: cellular and functional characterization. J Pharm Exp Ther 2001; 297: 876–87.
18. Calzi F, Bellasio R, Guiso G et al. Effect of piribedil and its metabolite, S584, on brain lipid peroxidation in vitro and in vivo. Eur J Pharmacol 1997; 338: 185–90.
19. Briley M. Noradrenergic mechanisms in Parkinson's disease. Trends Pharmacol Sci 1993; 14: 33–4.
20. Bloem В, van Vugt J, Beckley DJ. Postural instability and falls in Parkinson disease. Gait Disorders. Advanes in Neurology. Philadelphia: Lippincott Wiliams & Wilkins. 2001; 87: 209–23.
21. Narabayashi H, Kondo T, Yokochi F et al. Clinical effects of L-threo-3,4-dyhydroxyphenylserine in cases of parkinsonism and pure akinesia. Adv Neurol 1987; 45: 593–602.
22. Brefel-Courbon C. Parkinson's disease and the noradrenaline system. Presse Med 2002; 31: 1240–2.
2. Schapira AHV. The management of Parkinson’s disease – what is new? Eur J Neurol 2011; 18 (Suppl. 1): 1–2.
3. Иллариошкин С.Н. Терапия паркинсонизма: возможности и перспективы. Cons. Med. Неврология (Прил.). 2009; 1: 35–40.
4. Poewe W, Antonini A, Zijlmans JC et al. Levodopa in the treatment of Parkinson's disease: an old drug still going strong Clin Interv Aging 2010; 7: 229–38.
5. Quinn N. Drug treatment of Parkinson’s disease. BMJ 1995; 310 (Suppl. 9): 575−9.
6. Rascol O, Slaoui T, Regragui W et al. Dopamine agonists. W.C.Koller, E.Melamed (eds). Handbook of Clinical Neurology; v. 84: Parkinson’s disease and related disorders. Part II. Elsevier 2007; p. 73–92.
7. Sibley DR, Monsma FJ. Trends Pharmacol Sci 1992; 13: 63–9.
8. Rodbell M. Signal transduction: evolution of an idea. N.Ringertz (ed). Nobel Lectures, Physiology or Medicine 1991–1995. Singapore: World Scientific, 1997; p. 220–36.
9. Schapira AHV, Olanow CW. Neuroprotection in Parkinson’s disease. Mysteries, Myths, and Misconceptions. JAMA 2003; 291: 358–64.
10. Nishibayashi S, Asanuma M, Kohno M et al. Scavenging effects of dopamine agonists on nitric oxide radicals. J Neurochem 1996; 67: 2208–11.
11. Stocchi F. Neuroprotection in Parkinson’s disease: clinical trials. W.C.Koller, E.Melamed (eds). Handbook of Clinical Neurology, Vol.84: Parkinson’s disease and related disorders. Part II. Elsevier 2007; 17–29.
12. Голубев В.Л., Садеков Р.А., Пилипович А.А. Проноран в лечении болезни Паркинсона. Лечение нервных болезней. 2002; 3: 13–7.
13. Kwiecinski H, Fedorova N, Takats A et al. A multicenter trial of Piribedil as early adjunct treatment for Parkinson’s disease: Piribedil International Study Group (PISG). Neurology 2002; 58: A163.
14. Truelle JL, Chanelet J, Bastard J et al. Piribedil, dopaminergic agonist: prolonged clinical and electrophysiological study in 60 parkinsonian patients. Presse Med 1977; 6: 2987–90.
15. Ziegler M, Rondot P. Activity of piribedil in Parkinson’s disease: a multicenter study. Press Med 1999; 28: 1414–8.
16. Пилипович А.А., Голубев В.Л. Влияние пронорана на когнитивные и аффективные нарушения при болезни Паркинсона. Журн. неврол. и психиатр. им. С.С.Корсакова. 2005; 4: 41–7.
17. Millan MJ, Cussac D, Milligan G et al. Antiparkinsonian agent Piribedil displays antagonism properties at native, rat, and cloned, human a2-adrenoreceptors: cellular and functional characterization. J Pharm Exp Ther 2001; 297: 876–87.
18. Calzi F, Bellasio R, Guiso G et al. Effect of piribedil and its metabolite, S584, on brain lipid peroxidation in vitro and in vivo. Eur J Pharmacol 1997; 338: 185–90.
19. Briley M. Noradrenergic mechanisms in Parkinson's disease. Trends Pharmacol Sci 1993; 14: 33–4.
20. Bloem В, van Vugt J, Beckley DJ. Postural instability and falls in Parkinson disease. Gait Disorders. Advanes in Neurology. Philadelphia: Lippincott Wiliams & Wilkins. 2001; 87: 209–23.
21. Narabayashi H, Kondo T, Yokochi F et al. Clinical effects of L-threo-3,4-dyhydroxyphenylserine in cases of parkinsonism and pure akinesia. Adv Neurol 1987; 45: 593–602.
22. Brefel-Courbon C. Parkinson's disease and the noradrenaline system. Presse Med 2002; 31: 1240–2.
Авторы
С.Н.Иллариошкин, Е.А.Карпова, И.А.Иванова-Смоленская, Л.А.Черникова
ФГБУ Научный центр неврологии РАМН, Москва
ФГБУ Научный центр неврологии РАМН, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.